Abnormal glucose tolerance (Abnl-GT) is due to an imbalance between insulin resistance (IR) and β-cell function. Recent data from Africa suggest that β-cell failure contributes to the development of Abnl-GT more than previously recognized. Therefore in 490 African-born Blacks living in the United States (Male 64%, Age 38±10y (mean±SD), we compared the prevalence and metabolic characteristics of Abnl-GT due to IR (Abnl-GT-IR) to Abnl-GT due to β-cell-failure (Abnl-GT-β-cell-failure). Based on OGTT, Abnl-GT was defined as fasting glucose≥100 mg/dL or 2h glucose≥140 mg/dL. Visceral adipose tissue (VAT), triglyceride (TG) and 10y-Cardiovascular Risk-Score (CVD-Risk-Score) were measured. The cohort was divided into quartiles of HOMA-IR and quartiles of Matsuda Index. IR was defined by thresholds at the upper quartile of HOMA-IR (≥2.05) or the lowest quartile of the Matsuda index (≤2.97). Diagnosis of Abnl-GT-IR required both Abnl-GT and IR. Abnl-GT-β-cell failure was defined as Abnl-GT without IR. Abnl-GT occurred in 38% (181/490) of Africans. Of the Africans with Abnl-GT, insulin resistance occurred in 38% (68/181) and β-cell-failure occurred in 62% (113/181) of the Africans. Compared to Africans with Abnl-GT-β-cell-failure, Africans with Abnl-GT-IR had higher BMI (31.0±4.5 vs. 27.4±3.8 kg/m2), VAT (160±72 vs. 111±65 cm2), TG (106±52 vs. 77±39 mg/dL) (all P<0.001) and CVD-Risk-Score (26±24 vs. 19±17) (P<0.05). Independent of whether IR was defined by HOMA-IR or Matsuda index, results were similar. Alcohol intake was higher in the Abnl-GT-IR group (P=0.05), but other potential confounders such as years in the United States, income, education, sedentary behavior and fiber intake did not differ. Overall, Abnl-GT-IR was less common than Abnl-GT-β-cell-failure, but the metabolic profile was worse in Abnl-GT-IR. To determine the clinical course for these two types of Abnl-GT, prospective study design needs to include methodology to both diagnose Abnl-GT and elucidate the cause.

Disclosure

M. Ishimwe: None. J. Ha: None. A. Sherman: None. A. E. Sumner: None. T. Hormenu: None. E. M. Shoup: None. N. H. Osei-tutu: None. A. Patterson: None. A. Wentzel: None. M. Bagheri: None. C. Dubose: None. L. Mabundo: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.